# Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma

> **NCT03614364** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 41 (estimated)

## Conditions studied

- Salivary Duct Carcinoma

## Interventions

- **DRUG:** nanoxel
- **DRUG:** herzuma

## Key facts

- **NCT ID:** NCT03614364
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-20
- **Primary completion:** 2022-09
- **Final completion:** 2023-08
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03614364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03614364, "Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03614364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*